PITTSBURGH, Aug. 6, 2024
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on
August 5, 2024, its Board of
Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding
share of the Company's common stock. The dividend is payable on
September 13, 2024, to shareholders
of record as of the close of business on August 23, 2024.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a
global healthcare company uniquely positioned to bridge the
traditional divide between generics and brands, combining the best
of both to more holistically address healthcare needs globally.
With a mission to empower people worldwide to live healthier at
every stage of life, we provide access at scale, currently
supplying high-quality medicines to approximately 1 billion
patients around the world annually and touching all of life's
moments, from birth to the end of life, acute conditions to chronic
diseases. With our exceptionally extensive and diverse portfolio of
medicines, a one-of-a-kind global supply chain designed to reach
more people when and where they need them, and the scientific
expertise to address some of the world's most enduring health
challenges, access takes on deep meaning at Viatris. We are
headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com
and investor.viatris.com, and connect with us
on LinkedIn, Instagram, YouTube and X (formerly
Twitter).
Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward looking statements may include
statements that Viatris' Board of Directors declared a quarterly
dividend of $0.12 per share for each
issued and outstanding share of the Company's common stock payable
on September 13, 2024, to
shareholders of record as of the close of business on August 23, 2024. Because forward-looking
statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to: actions and decisions of healthcare and pharmaceutical
regulators; changes in healthcare and pharmaceutical laws and
regulations in the U.S. and abroad; any regulatory, legal or other
impediments to Viatris' ability to bring new products to market,
including but not limited to "at-risk" launches; Viatris' or its
partners' ability to develop, manufacture, and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings, and the impact of any such proceedings; the
possibility that Viatris may be unable to realize the intended
benefits of, or achieve the intended goals or outlooks with respect
to, its strategic initiatives; the possibility that Viatris may be
unable to achieve intended or expected benefits, goals, outlooks,
synergies, growth opportunities and operating efficiencies in
connection with divestitures, acquisitions, other transactions or
restructuring programs, within the expected timeframes or at all;
goodwill or impairment charges or other losses related to the
divestiture or sale of businesses or assets; Viatris' failure to
achieve expected or targeted future financial and operating
performance and results; the potential impact of public health
outbreaks, epidemics and pandemics; any significant breach of data
security or data privacy or disruptions to our information
technology systems; risks associated with international operations;
the ability to protect intellectual property and preserve
intellectual property rights; changes in third-party relationships;
the effect of any changes in Viatris' or its partners' customer and
supplier relationships and customer purchasing patterns; the
impacts of competition; changes in the economic and financial
conditions of Viatris or its partners; uncertainties and matters
beyond the control of management, including general economic
conditions, inflation and exchange rates; failure to execute stock
repurchases consistent with current expectations; stock price
volatility; and the other risks described in Viatris' filings with
the Securities and Exchange Commission (SEC). Viatris routinely
uses its website as a means of disclosing material information to
the public in a broad, non-exclusionary manner for purposes of the
SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no
obligation to update these statements for revisions or changes
after the date of this press release other than as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-announces-second-quarter-2024-dividend-302214970.html
SOURCE Viatris Inc.